Motif’s lead antibiotic candidate, iclaprim, met the trial’s endpoint: non-inferiority to vancomycin, the current standard-of-care antibiotic for patients with acute bacterial skin and skin structure infection (‘ABSSSI’).
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Major milestone reached with successful Phase 3 trials
- Published:
02 May 2018 -
Author:
Barry Gibb -
Pages:
20
Motif’s lead antibiotic candidate, iclaprim, met the trial’s endpoint: non-inferiority to vancomycin, the current standard-of-care antibiotic for patients with acute bacterial skin and skin structure infection (‘ABSSSI’).